HERMES ARZNEIMITTEL vs Roche

Havas Retains Hermes Arzneimittel Media Account

Havas Media’s Frankfurt office has been confirmed as Hermes Arzneimittel’s media agency after winning a multi-stage pitch. From 2027 the agency will take responsibility for the full media budget — including digital activities — in an assignment valued in the mid single-digit million euro range. Havas, which has served Hermes since 2013, will assume additional brand duties that, together with digital responsibilities, will double the media volume it manages for the client. Hermes’ brands cited include Antibrumm (Anti Brumm), Compeed (blister plasters), Algorvir (algovir), Biolectra Magnesium, Betaisodona and doc. The win was reported by Horizont on 17 August 2026.

• Havas Media (Frankfurt) won Hermes Arzneimittel’s full media account following a multi-stage pitch.
• Havas will assume responsibility for the account from 2027, including digital activities.
• The account is valued in the mid single-digit million euro range.

Wirz Launches Healthcare Consulting Unit Wirz Pulse

Swiss agency group Wirz has launched 'Wirz Pulse', a specialized consulting offering for the healthcare market, targeting hospitals, insurers, and pharma/medtech companies. The service aims to support healthcare organizations in positioning, change management, and growth. Wirz will collaborate with organizations to develop a strategic direction translated into positioning, culture, offerings, communication, and experiences. Six programs cover transformation, brand identity, patient journey, work culture, innovation, and digital experience. The launch responds to labor shortages, cost pressure, digitalization, and evolving patient needs, as well as new fields like personalized medicine and longevity. Existing healthcare mandates include Roche, University Hospital Zurich, CSS, Interpharma, and Rheumaliga Schweiz, from which Wirz derived recurring challenges and success factors.

• Wirz Group launches 'Wirz Pulse' consulting service for healthcare sector.
• Targets hospitals, insurers, pharma, and medtech companies.
• Offers six programs: transformation, brand identity, patient journey, work culture, innovation, digital experience.

Roche and Ypsomed Stay Top in Swiss Reputation Ranking

Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.

• Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method.
• The study measured presence and tonality for 40 pharma and medtech companies and computed a Reputation Score between 0 and 100 across six reputation dimensions.
• In the Pharma & Biopharma category, Roche ranked first, followed by MSD, Novartis, Sandoz and AstraZeneca.

Roche Pharma Day 2026 announced

Roche Pharma Day 2026 will be held on Monday, 28th September 2026, 09:00am BST. More details available via the investor update.